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Summary 
Tumor infiltrating lymphocytes (TILs) derived from tumor-bearing patients recognize tumor- 
associated antigens presented by major histocompatibility complex (MHC) class I  molecules. 
The infusion of TIL586 along with interleukin (IL) 2 into an autologous patient with meta- 
static melanoma resulted in the objective regression of tumor. A gene encoding a tumor anti- 
gen recognized by TIL586 was recently isolated and shown to encode gp75. Here we report 
that an antigenic peptide, MSLQRQFLI:k, recognized by TIL586 was not derived from the 
normal gp75 protein. Instead, this nonamer peptide resulted from translation of an alternative 
open reading frame of the same gene. Thus, the gp75 gene encodes two completely different 
polypeptides, gp75 as an antigen recognized by immunoglobulin G  antibodies in sera from a 
patient with cancer, and a 24-amino acid product as a tumor rejection antigen recognized by T 
cells. This represents the first demonstration that a human tumor rejection antigen can be gen- 
erated from a normal cellular gene using an open reading frame other than that used to encode 
the normal protein. These findings revealed a novel mechanism for generating tumor antigens, 
which may be useful as vaccines to induce tumor-specific cell-mediated immunity against cancer. 
T 
he adoptive transfer of tumor infiltrating lymphocytes 
(TILs)  1 can mediate tumor regression in patients with 
metastatic melanoma (1, 2), suggesting that tumor rejection 
antigens recognized by T  cells exist on these tumor cells. 
The availability of such T cells has made it possible to clone 
and sequence the genes that encode human melanoma an- 
tigens (3-7). The antigens identified so far from human mel- 
anoma can be divided into two classes based on their ex- 
pression pattern. The antigens of the first class are encoded 
by genes that are expressed only in tumor and testis, but not 
other normal human tissues. MAGE1, MAGE3, and BAGE 
are examples of this class (8-10). The second class of anti- 
gens represents differentiation antigens encoded by genes that 
are expressed only in melanocytes, melanomas, and retina. 
MART-1/Melan-A, gpl00, and tyrosinase are examples of 
this class (11-16). All these antigens  are nonmutated self- 
proteins. Identification of the antigenic epitopes recognized 
by T  cells derived from the corresponding gene products is 
important  not  only for understanding  the  mechanism  of 
immune response to serf-antigens, but also for developing 
new, effective immunotherapeutic strategies  with these an- 
1Abbreviations used in this paper: ORF, open reading frame; TIL, tumor- 
infiltrating lymphocyte. 
tigens  or synthetic peptides  for the  treatment  of patients 
with cancer. 
Previous studies showed that the infusion of TILS86 plus 
IL-2 into an autologous patient with melanoma resulted in 
the objective regression of metastases  (17).  More recently, 
we cloned the gene  TRP-1,  or gp75,  encoding the tumor 
antigen  recognized by TIL586 in  association with  HLA- 
A31  (18).  Interestingly, the gene product, gp75, was origi- 
nally identified as an antigen recognized by IgG antibodies 
in the serum from a patient with rnatastatic  melanoma (19). 
The gene  was  found to  be  expressed only in  melanoma, 
normal melanocyte cell lines, and retina, but not in other 
normal tissues tested (18, 20). Therefore, this gene is a mem- 
ber  of the  second  class of antigens  including MART-l/ 
Melan-A, gpl00, and tyrosinase. 
In this study we report the identification of the antigenic 
epitope from the  TRP-1  gene. ExoIII/S1 deletion analysis 
allowed us to localize the epitope in a small DNA fragment 
but  failed to  identify the  epitope from the  normal  gp75 
protein using synthetic peptides. Surprisingly, the peptide 
recognized by TIL586 was derived from the gene product 
translated  from an  alternative  open  reading frame  of the 
same  gene.  Substitution  of the  ATG  start  codon  of this 
short open reading frame with ATC  at  nucleotides 294- 
296 resulted in a complete loss  of the ability to stimulate 
cytokine release from TIL586.  Cold-target inhibition ex- 
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of competing for T  cell recogmtion with  a  naturally pro- 
cessed peptide present on the tumor cells. Six T  cell clones 
generated from the TIL586 cell line were capable of recog- 
nizing 586reel tumor cells, 586EBV B cells pulsed with this 
peptide, and normal melanocytes in an HLA-A31-restricted 
fashion, also suggesting that the gene product encoded by 
the alternative open reading frame might be present in the 
tumor cells as well as the normal melanocytes. The biolog- 
ical significance and the mechanism by which the overlap- 
ping open reading frames are translated from a single cellu- 
lar gene are discussed. 
Materials and Methods 
Chemicals and Reagents.  The following chemicals and reagents 
were purchased from the sources indicated: RPMI 1640,  AIM-V 
media, lipofectamine, G418 (GLBCO BILL, Gaithersburg, MD); 
the eukaryotic expression vector pC1%3 (Invitrogen, San Diego, 
CA); anti-HLA-A31 mAb (One lambda, Canoga Park, CA); anti- 
IgM antibody conjugated with FITC (Vector Laboratories, Inc., 
Burlingame, CA). 
CTLs and Cell Lines.  TIL586  were isolated from the tumor 
specimen of a patient with metastatic melanoma and grown in 
medium  containing IL-2 (6,000  IU/ml)  (Cetus Corp., Emory- 
ville, CA) for 32-60 d as previously described (17). TIL586 were 
predominantly CD8 §  T  cells.  TILl200  were grown under the 
same conditions as described for TIL586. The T  cell clones were 
generated by the limiting dilution method from the TIL586 cell 
line, and then they were expanded in AIM-V medium containing 
6,000 IU/ml IL-2. 
Melanoma cell lines 397mel, 397mel/A31,586mel, 624mel, and 
EBV-transformed B cell lines 586EBV and 1510EBV  were estab- 
lished in  this laboratory and  cultured in  ILPMI  1640  medium 
containing 10% FCS. Normal cultured melanocytes derived from 
infant foreskin (NHEM680, purchased from Clonetics Corp., San 
Francisco,  CA)  were  cultured  in  melanocyte  growth  medium 
(MGM; Clonetics Corp.). The COS-7 cell line was provided by 
Dr. W. Leonard (National Institutes of Health, Bethesda, MD). 
GM-CSF Secretion Assay.  DNA transfec~on and GM-CSF assay 
were done as previously described (18). Briefly, 200 ng ofplasmid 
DNA pools or clones and  50  ng of the  HLA-A31  DNA were 
mixed with 2 I~1 oflipofectamine in 100 ttl of DMEM for 15-45 
min.  The  DNA-lipofectamine mixture  was  then  added to  the 
COS-7  (5  ￿  104) cells and incubated overnight. The following 
day,  cells were  washed  twice  with  DMEM  medium.  TIL586 
were added at a concentration of 105 cells/well in AIM-V me- 
dium containing 120  IU/ml of IL-2. After 18-24-h  incubation, 
100 I~1 ofsupernatant was collected, and GM-CSF was measured 
in  a  standard ELISA assay  (1% &  D  Systems Inc.,  Minneapohs, 
MN). For peptides, 586EBV,  1510EBV, and T2 cells were incu- 
bated wath  peptides at 37o(  TM  for 90 nun  and then washed three 
times  with  AIM-V  medium  containing  120  IU/ml  of IL-2. 
TIL586 were added and incubated for an additional 18-24 h, and 
100 ~l ofsupematant was collected for GM-CSF assay. 
Exo III/$1 Deletion Constructions and PCR Fragments.  To make a 
series of deletions, the  pcDNA776  plasmid DNA was  digested 
with XbaI and filled in with (x-phosphorothioate deoxyribonu- 
cleotide triphosphates to  block Exolll nuclease  digestion. The 
pcDNA776 plasmid is a derivative of the pcDNA3 vector con- 
raining a  2.4-kb DNA fragment of the gp75 gene and a  CMV 
promoter for  directing transcription. The  linearized DNA was 
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subjected to  the  second  restriction enzyme  XhoI  digestion to 
generate one end sensitive to Exolll. ExolII nuclease/Mung bean 
nuclease deletion was performed according to the manufacturer's 
instructions  (Stratagene Inc.,  La Jolla, CA).  PC1% amplification 
was performed at 94~  for 2 rain followed by 25 cycles of 94~ 
for  1 rain,  55~  for 45  s,  and  72~  for  1  min.  Primers gpN 
(5'-AGAATGAGTGCTCCTAAACTCCTCTCTCTGGG)  and 
gp11B (5'-CATGTGAGAAAAGCTGGTCCCTCA) were used 
to  generate the DNA fragment  (1--667)  and then  cloned into 
the  pC1%3 expression  vector  to  produce  pPC1%110. Plasmids 
pPCtL210 and pPCR220 were pCIL3 vectors containing DNA 
insertion fragments amplified by using primers gp-1  (5'-TGG- 
ATATGGCAAAGCGCACAACTC) and gp11B, gp-1, and gp22 
(5'-TAAATGGAAATGTTCTCAAATTGTGGCGTG), respec- 
tively. 
Cytotoxic Lysis Assays.  Cytolytic assays were  done  as  previ- 
ously described (16).  Briefly, the target cells were labeled with 
chromium for 90 nun.  After washing three times, the cells were 
incubated with  peptides at  a  concentration  of 1 ~g/ml for  90 
rain. The cells were washed again, counted, and then mixed with 
TIL586 at the indicated E/T ratio. Chromium release was mea- 
sured after 4  h  incubation. The  peptides were synthesized by a 
solid-phase method using a peptide synthesizer (model AiMS 422; 
Gilson Co., Inc., Worthington, OH). Some peptides were puri- 
fied by HPLC and were >98% pure. For titration of the O1%F3P 
peptide recognized by TIL586, 586EBV B  cells were incubated 
with various concentrations of the purified O1%F3P peptide. Per- 
centage of specific lysis was determined from the equation (A - 
B)/(C  -  B)  ￿  100,  where  A  is  lysis  of 586EBV  B  cells by 
TIL586  in the presence  of a  peptide, B  is spontaneous  release 
from 586EBV B  cells in the presence of the same peptide but in 
the absence of effector cells, and C  is the maximum chromium 
release. Cold-target inhibition of cytolysis was performed using 
51Cr-labeled 586mel or 624mel cells as "hot" targets and 586EBV 
B and T2 cells pulsed with peptides as "cold" targets. 
Site-directed Mutagenesis.  For carrying out site-directed mutagen- 
esis,  we  used  mutated  primers  GPMUT1  (5'-GCCATGGGC- 
AGAGATGATCGGGAGGTCTGGCCCTTGCGCTTCTTC- 
AATAGGACAT_CTCACTGCAAC) and the non-mutated primer 
GPA1 (5'-AAGATCTGGGCCCGGACAAAGTGGTTCTITrC) 
to generate a PC1% fragment containing a mutation (G to C) at 
nucleotide 296. The wild-type DNA fragments were amplified by 
the  use  of primers  GPF1  (5'-GAAGATCTGCCATGGGCA- 
GAGATGATCGGGAGGTCTG),  GPE1  (5'-GAATTCGTTG 
TGT CCTGAGAAATTGCCGTTG), GPE2 (5'-GAATTCGAC- 
TATGAGAACCCTCTGGTCACAGGC),and  GPA1,  as  indi- 
cated by arrowheads in Fig. 3 A. The purified PC1% products were 
then cloned into the pC1%3 expression vector. All plasmids con- 
taining PCR fragments were sequenced to confirm the orienta- 
tion and nucleotide sequence. 
Results 
Localization  of  the  Antigenic  Peptide(s)  Recognized  by 
TIL586.  To identify the antigenic epitope from gp75, we 
generated a series of nested deletions ofgp75 gene from the 
3' end using ExolII/S1 nuclease as well as additional DNA 
fragments from gp75 by PC1L amplification (Fig. 1 A). We 
chose  the  pcDNA776  construct  as  a  starting material for 
deletion studies.  This clone, which was initially identified 
by a library screening, conferred the ability to stimulate cy- 
tokine  release from  TIL586.  Since  the  goal  of this  study 
Antigen was to identify the epitope recognized by TIL586, we used 
fragments of the  truncated  form of gp75,  instead  of full- 
length cDNA so that we could quickly locate the epitope 
in  a  relatively small DNA fragment.  These  deletion  con- 
structs were then transfected into COS-7 cells together with 
the  pBK-CMV  plasmid  containing  the  HLA-A31  gene 
(18).  After 24 h, the transfected COS-7 cells were tested to 
determine which construct could stimulate cytokine release 
by TIL586. A small truncated DNA fragment ranging from 
nucleotide 247 to 771, which lacked the normal gp75 initi- 
ation codon, retained the ability to stimulate GM-CSF re= 
lease by TIL586, suggesting that the  epitope recognized by 
TIL586 was located in the DNA fragment containing nucle- 
otides from 247  to 771.  Since there is  an ATG start co- 
don  in  a  relatively  good  context  of  Kozak  sequence 
(GATATGG) located  at  nucleotides  445-447  and  in  the 
same frame as gp75 open reading frame, we reasoned that 
the epitope recognized by TIL586 might be located in the 
region  from nucleotide  445  to  771.  Therefore,  we  con= 
structed pPCl~210  and pPCR220,  which were derivatives 
of the pCR.3  expression vector and  contained  an internal 
ATG codon in frame with  gp75  (GATATGG) located at 
445 bp as a start codon for translation of the truncated normal 
gp75 protein.  However, neither pPCR.210  nor pPCR.220 
conferred the  ability to  stimulate  cytokine secretion from 
TIL586 after cotransfection of COS-7 with the HLA-A31 
gene (Fig.  1 B), suggesting that the epitope was located up- 
stream of these fragments. Therefore, an additional plasmid 
pD776A was constructed that contained the nucleotide se- 
quence from 247 to 442 and did not have any ATG codon 
in the same frame as gp75, but did contain two ATG codons 
in different open reading frames relative to gp75.  Surpris- 
ingly, this plasmid strongly stimulated cytokine release from 
TIL586 when cotransfected with A31  cDNA into COS-7 
cells.  The plasmid pPCK110 containing the authentic start 
codon ofgp75 stimulated severalfold lower cytokine release 
than did pDel 5  or pD776A when  cotransfected with the 
HLA-A31 gene (Fig.  1 B). These results suggested that the 
epitope(s)  recognized  by TIL586 were  located  in  the  re- 
gion from nucleotides 247 to 442. 
Although this region (nucleotides 247--442) did not have 
any  ATG  start  codon  in  the  normal  gp75  open  reading 
frame, initiation of translation from non=ATG codons such 
as ACG, CTG, and GTG had been reported in some cases 
(21-23).  To identify the  epitope in  this region,  we made 
synthetic  peptides  based on  the  peptide  binding motif of 
HLA-A31  (hydrophobic  residue  at  position  2  and  posi- 
tively  charged  residue  at  the  COOH  terminus)  (Fig.  2) 
(24).  The  majority of the  peptides  selected for this  study 
were nonamers, although some were 10 mers and 11 mers. 
We pulsed these peptides onto 586EBV B  cells  and tested 
the  ability  of these  cells  to  stimulate  cytokine  release  by 
TIL586 (Table 1). One peptide, AACDQt~VLIVRR, very 
weakly induced GM-CSF release from TIL586. However, 
this  peptide  failed  to  sensitize  peptide-loaded  586EBV  B 
for lysis by TIL586 (Table 1). Because this peptide weakly 
stimulated cytokine release from TIL586 only when incu- 
bated with 586EBV B cells at high concentrations (> 1 )xg/ 
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Figure 1.  Location  of  the gp75 nucleotide sequence coding  for the anti- 
genic peptides recognized by TIL586. (A) The full-length cDNA com- 
prising the 1584-bp open reading frame of gp75 is shown. Nucteotides 
are numbered from  the start codon, which translates into a protein con- 
sisting of a leader sequence and the mature gp75. pcDNA776 is a partial 
cDNA ofgp75 that lacks the first 246 nucleotide coding region, and it 
was isolated from a cDNA library using an assay based on its ability to 
stimulate GM-CSF secretion by TIL586 when cotransfecting COS-7 
along with the HLA-A31 gene. A series of deletion constructs and PCR 
DNA fragments  were made. pD776A is a derivative  ofpcDNA776 a~er 
digestion with the ApaI restriction enzyme. (B)  GM-CSF release by 
TIL586. GM-CSF secretion by TIL586 was measured atier coculture 
with COS-7 cotransfected  with the DNA fragments  shown in A and the 
HLA-A31 gene. Control stimulator cells include 586mel, 397mel/A31  § 
COS-7  alone, and  COS-7 transfected either with HLA-A31  or 
pcDNA776 cDNA. 
ml) and did not sensitize the target cells for lysis by TIL586 
even at 10 I~g/ml ofpeptide concentration (data not shown), 
it may not represent the predominant T  cell epitope recog- 
nized by TIL586. 
To further define the region containing the predominant 
T  cell epitope, we constructed two additional plasmids con- 
taining PCK fragments amplified by primers GPF1, GPE1, 
and GPE2, respectively (Fig.  3 A). As shown in  Fig.  3  B, 
both  plasmids  conferred  the  abihty  to  stimulate  cytokine 
release by TIL586 in association with  HLA-A31, suggest- ~.AGTGCTCCTAAACTCCTCTCTCTGGGCTGTATCTTCTTCCCCT~GCTACTTTTTCAG  60 
ORFI  M  S  A  P  K  L  L  S  L  G  C  I  F  F  P  L  L  L  F  Q 
CAGGCCCGGGCTCAATTCCCAAGACAGTGTGCCACTGTTGAGGCT~GAAGTGGTATG  120 
ORFI  Q  A  R  A  Q  F  P  R  Q  C  A  T  V  E  A  L  R  S  G  M 
TGq~CCAGACCq~TCC  CCTGTGTC~CTGGGACAGAC  CGC  TGTGGCTCATCATCA  180 
ORFI  C  C  P  D  L  S  P  V  S  G  P  G  T  D  R  C  G  S  S  S 
GGGAGGGGCAGATGTGAGGCAGTGACTGCAGACTCCCGGCCCCACAGCCCTCAGTATCCC  240 
ORFI  G  R  G  R  C  E  A  V  T  A  D  S  R  P  H  S  P  Q  Y  P 
CATGATGGCAGAGA~C-ATCGGGAGGTCTGGCCCT~TTCTTCAATAGGACA%~"PCAC  300 
ORFI  H  D  G  R  D  D  R  E  V  W  P  L  R  F  F  N  R  T  C  H 
ORF2  M  I  G  R  S  G  P  C  A  S  S  I  G  H  V  T 
ORF3  M  8  L 
TGCAACGG~q'I'PCTCAGGACACAACTGTGGGACGTGCCGTCCTGGCTGGAGAGGAGCT  360 
OF~Wl  C  N  G  N  F  S  G  H  N  C  G  T  C  R  P  G  W  R  G  A 
ORF2  A  T  A  I  S  L  Q  D  T  T  L V  G  D  R  A  V  L  W  A  G  E  E  L  C 
OKF3  O  R  O  T  Q  W  P  S  L  E  R  S 
GCCTGTGACCAGAGGGTT~TAGTCAGGAGAAATCTTC~CTTAAGTAAAGAAGAA  420 
ORFI  A  C  D  Q  R  V  L  I  V  R  R  N  L  L  D  L  S  K  E  E 
ORF2  P  V  T  R  G  F  S  STOP 
ORF3  L  STOP 
ApaI 
AAGAACCAC~TCCGC-GCCCTC~T&%~SC42AAAGCGCACAAC~PCACCCT..  .ATATGA 1584 
ORFI  K  N  H  F  V  R  A  L  D  M  A  K  R  T  T  H  P 
Figure  2.  The  nucleotide,  amino  acid  sequence,  and  open  reading 
frames of the gp75 gene. The partial nucleotide and anaino acid sequences 
of the first 157 amino acids were shown from the start codon for transla- 
tion of ORF1  (gp75). The DNA fragment that conferred the ability to 
stimulate GM-CSF release from TIL586 is underlined. Two putative start 
codons, ATG (254-256) and ATG (294-296), are in bold and may result 
in  the  translation of ORF2 and ORF3,  respectively. The peptide se- 
quence recognized by TIL586 from ORF3 is in bold and underlined. 
ing  that  the  epitope  recognized by  T  cells was  encoded 
within an  82-nucleotide sequence  between bases 247  and 
329 of the gp75 cDNA. 28 overlapping peptides (9 mers or 
10  mers)  in  the  gp75  open  reading frame  (ORF)  1  were 
synthesized based on  the  amino  acid sequence  of gp75  in 
Table 1.  Screening  of Synthetic Peptides with Reactivity to TIL586 
this region, but none were found to stimulate GM-CSF re- 
lease or sensitize 586EBV  B  cells for lysis by TIL586  (data 
not shown). 
Antigenic Peptides Resulted from Translation of an Alternative 
Open Reading Frame of the gp 7  5 Gene.  The failure to identify 
an epitope recognized by TIL586 in this small region sug- 
gested to us that alternative open reading frames might be 
translated. Two ATG codons in the relatively good context 
were present in this region (nucleotides 247-442) in differ- 
ent  open  reading frames  from  ORF1  (Fig.  2).  Translation 
from  the  first  ATG  (251  GAGATGA257)  resulted  in  a 
open reading frame encoding 45 amino acids open reading 
frame  2  (ORF2),  whereas  translation  starting  from  the 
ATG  located  between  nucleotides  294  and  296  (GAC- 
ATGT)  generated  a  24-amino  acid  gene  product  open 
reading frame  3  (ORF3)  (Fig.  2).  Three  peptides derived 
from  ORF2  and  two  peptides from  ORF3  were  selected 
and synthesized on the basis of the HLA-A31 binding motif 
(Table  2  and  Fig.  2).  Surprisingly,  one  peptide,  MSL- 
QRQFLR  (designated  as  ORF3P),  which  derived from 
ORF3,  was  strongly recognized by  TIL586  when  pulsed 
onto  586EBV  B  cells  (Table  2).  The  recognition  of the 
ORF3P  peptide  (MSLQRQFLR)  by  TIL586  was  ob- 
served only when the peptide was pulsed onto autologous 
586EBV B cells and 1510EBV B  (A31 +) cells, but not when 
peptide was loaded onto  T2  (non-HLA-A31) cells (Fig. 4 
A), suggesting that  recognition of this peptide by TIL586 
was HLA-A31 restricted. The peptide mass of ORF3P was 
confirmed  by  mass  spectrometry.  As  shown  in  Fig.  4  B, 
Target cells pulsed with peptide 
TIL586 
GM-CSF release  Percent specific lysis (E/T ratio 20:1) 
Peptides from ORF1 (gp75) 
586EBV  +  peptide DDREVWPLR  <50  <10 
586EBV  +  peptide VWPLRFFNR  <50  <10 
586EBV  +  peptide SGHNCGTCR  <50  <10 
586EBV  +  peptide CGTCRPGWR  <50  <10 
586EBV  +  peptide ACDQRVLIVR  <50  <I0 
586EBV  +  peptide ACDQRVLIVRR  <50  < 10 
586EBV  +  peptide LWDVPSWLER  <50  <10 
586EBV  +  peptide AISQDTTVGR  <50  <10 
586EBV  +  peptide AACDQRVLIVR  250  < 10 
586EBV  +  peptide DQRVLIVRR  <50  <10 
586EBV  +  peptide IVRRNLLDLSK  <50  <10 
586EBV  +  peptide LSKEEKNHFVR  <50  <10 
586EBV  +  none  <50  <10 
586mel  +  none  >5,000  <45 
586EBV cells  were incubated with individual peptide at a concentration of l  b~g/ml for 90 min. GM-CSF release was measured after coincubation 
of peptide-loaded 586EBV cells with TIL586. GM-CSF secretion by TIL586 alone without stimulators was subtracted. 586EBV was an EBV-trans- 
formed B cell line expressing HLA-A31. Cytotoxic lysis of peptide-pulsed 586EBV by TIL586 was done in a 4-h S~Cr release assay. 
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Figure  3.  An antigenic peptide and translation of an alternative open 
reading frame. (A) Location and length of PCR fragments amplified by 
PCR. DNA fragments were obtained by PCR amplification and were 
then cloned into the pCR3 expression vector. Substitution of  ATG at po- 
sitions 294-296 with ATC was made as described in Materials and Meth- 
ods. (B) Test of DNA fra~gnents and mutation constructs to stimulate cy- 
tokine release from TIL586. GM-CSF release assay  was done as in Fig. 1. 
TIL586  lysed  586EBV  B  cells  pulsed  with  the  ORF3P 
peptide, but failed to lyse 586EBV B cells pulsed with an ir- 
relevant peptide,  which  met the  criterion  of the  peptide- 
binding  motif of HLA-A31  or  T2  cells  pulsed  with  the 
ORF3P  peptide.  Sensitization  for  lysis  by  the  peptide 
showed maximal effect at 100  nM,  though lytic activity was 
detected even at  1 nM of peptide concentration  (Fig.  4  C). 
TIL586 did not recognize either peptides MSLQRQFLRT 
or SLQRQFLRT,  or modified peptides containing substi- 
tution  of anchor  residues  at positions  2,  6  and  9  such  as 
M_LLQRQFLR,  ~QRQFLR,  MSLQRLFLR,  MSL- 
QRQFLE,  or MSLQRQFLK (Table 2). TIL586 only rec- 
ognized the peptide ~QRQFLR  containing a substitu- 
tion  of Ser  with  Ala  at  position  2  compared  with  the 
peptide MSLQRQFLR (Table 2). 
Translation of ORF3 Is Necessary  for Generating the Antigenic 
Peptide.  Since there was a stop codon TAG (288-290) lo- 
cated  in  the  six  nucleotides  upstream  of the  ATG  start 
codon of ORF3 (294-296)  (Fig. 2), it was unlikely that the 
ORF3P peptide resulted from a frameshift. DNA sequence 
analysis  also confirmed that there was no deletion or inser- 
tion in the upstream region. To investigate if the ATG lo- 
cated at nucleotides  294-296  played an important role in 
translating the 24-amino acid product, we mutated ATGT 
(294-297)  to ATCT (294-297) to eliminate the translation 
of ORF3, which would result in a change ofCys CUGU) to 
Ser (UCU) in ORF1  (gp75) (Fig. 3 A). A plasmid contain- 
ing the mutated gene (pGFMUT1) was tested for its ability 
to confer recognition by TIL586 when cotransfected into 
COS-7 along with the HLA-A31 cDNA. Fig. 3 B showed 
that the mutated gene completely lost the ability to stimu- 
late  GM-CSF  release  by TIL586.  This  observation  indi- 
cated that ATG in ORF3 in nucleotide positions 294-296 
was required for translation of the 24-amino acid product, 
and therefore was essential for generating the T  cell epitope 
recognized by TIL586. 
Since the Met (ATG) is in position 1 of the peptide epi- 
tope,  and  the  mutation  of ATG  to  ATC  at  nucleotides 
294-296 resulted in a change of Met to Ile in position 1 of 
the peptide, we further investigated the possibility that the 
loss  of recognition of the mutated gene by TIL586 could 
be due to the loss of the ability of the mutated peptide to 
bind to MHC class I molecules. A  synthetic peptide (ISL- 
QRQFLR) with the same amino acid sequence as that en- 
coded by the mutated gene was made and tested for recog- 
nition  by TIL586.  It was found  that  the  synthetic  mutated 
peptide was still recognized by TIL586 at concentrations com- 
parable to that of the wild-type peptide  (data not shown). 
Furthermore,  when the same mutation was introduced into 
the full-length cDNA, no reactivity to TIL586 was observed, 
whereas  the  wild-type  cDNA  was  capable  of stimulating 
cytokine release from TIL586 at a level similar to pPCR- 
110  (data not shown). This is in agreement with the dele- 
tion  data,  indicating  that  TIL586  did  not  recognize pep- 
tide(s)  in other regions of the gene. These results suggested 
that the loss of recognition of the mutated gene containing 
an ATG to ATC substitution at nucleotides 294-296 by T 
cells  was  due  to  inhibition  of  translation  initiation  of 
ORF3. 
Recognition of the Antigenic Peptide on Tumor Cells As Well 
As Melanocytes.  To address the question of whether TIL586 
recognized a naturally processed peptide similar or identical 
to  the  ORF3P  peptide  on the  tumor cells,  we  examined 
the ability of the ORF3P peptide-pulsed 586EBV B  cells 
51  to inhibit lysis of  Cr-labeled 586mel in a cold-target inhi- 
bition  assay.  Significant  inhibition  of lysis  of 51Cr-labeled 
586mel was observed by 586EBV B  cells  pulsed with the 
ORF3P peptide but not by 586EBV B cells pulsed with ir- 
relevant peptide or T2 cells pulsed with the ORF3P peptide 
(Fig.  5 A), indicating that this peptide epitope was capable 
of competing with a naturally processed peptide on tumor 
ceils for T  cell recognition. As predicted, the ORF3P-loaded 
586EBV  B  cells  did not inhibit  lysis  of target 624mel by 
TILl200, which recognizes the gpl00 antigen in the HLA- 
A2 context, compared with 586EBV B alone (Fig. 5 B). To 
further test if T  cell clones can recognize both the ORF3P 
peptide-pulsed 586EBV B cells and tumor cell lines, T  cell 
clones were generated from the TIL586 cell line by limit- 
ing dilution  (1  cell/well in 96-well round bottom micro- 
plate)  and  further  expanded  in  culture.  Six T  cell  clones 
were capable of recognizing 586mel tumor cells,  586EBV 
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Figure 4.  Characterization of the antigentic peptide recognized by TIL586. (A) GM-CSF release by the HLA-A31-restricted TIL586 when coincu- 
bated with various stimulators. Transfection and cytokine assays were performed as in Fig. 1. 586mel and 397mel were included as positive and negative 
controls for the reactivity  of  TIL586. The ORF3P peptide was incubated with 586EBV (A31  +) and T2 (non-AM) cells at a concentration of 1 la,g/ml for 
90 rain. Stimulation of GM-CSF secretion by TIL586 significantly increased when coincubated with autologous 586EBV and allogeneic 1510EBV 
(A31+) cells pulsed with peptide ORF3P, but not when coincubated with either 586EBV alone or T2 (non-A31) cells loaded with the ORF3P peptide. 
(B) Cytotoxic lysis of  the target cells by TIL586. 586mel (-I-) and 397mel (-C]-) were used as positive and negative controls, respectively. 586EBV  B 
cells were incubated with OP~F3P (pep) (~),  with an irrelevant peptide (ipep) (--O-), or without peptide (--~), and T2 cells were pulsed with 
ORF3P (--O-) as marked. After incubation, TIL586 was added and mixed with the target cells. Cytolytic activity of  TIL586 was measured in a 4-h StCr 
release assay. (C) Titration of  the peptide concentration to sensitize the target cells for lysis by TIL586. 586EBV  cells were separately incubated with serial 
dilutions of  ORF3P (pep) (~)  or irrelevant peptides (ipep) (---O--)  and T2 cells with the ORF3P peptide (-O-) for 90 min. The cytolytic activity of 
TIL586 was evaluated in a 4-h StCr release assay at an E/T ratio of  40:1. 
B  cells  pulsed  with  the  ORF3P  peptide,  and  HLA-A31 
positive melanocytes, but not 397mel/A31  +  or 586EBV 
B  cells  alone.  Representative  data  are  shown  in  Fig.  6. 
These  results suggested that T  cell clones probably recog- 
nized a naturally processed peptide either similar or identi- 
cal to the ORF3P peptide on tumor cells and normal mel- 
anocytes. 
Since there is a 40-45% amino acid sequence identity of 
gp75 to tyrosinase, gpl00, and TRP-2, we tested the possi- 
bility that the peptide recognized by the T  cell clones was 
not derived from gp75,  but from one  of these  other pro- 
teins. We thus transfected COS-7 cells with HLA-A31 plus 
either tyrosinase, gp 100, or TRP-2 cDNAs, and found that 
none could be recognized by the six T  cell clones, whereas 
the  COS-7-transfected HLA-A31 and gp75 cDNA stimu- 
lated GM-CSF release from these clones (data not shown). 
A  computer database  search also indicated  that no known 
proteins,  including  tyrosinase,  gpl00,  and  TRP-2,  in  the 
available database contained amino acid sequences with the 
peptide-binding motif of HLA-A31 and significant similar- 
ity to the peptide epitope recognized by TIL586. 
Discussion 
Several antigenic  T  cell epitopes  derived from the nor- 
mal  open reading frame  of the  corresponding nonmutated 
shared  melanoma  antigens  such  as  tyrosinase,  MART-l/ 
Melan-A, and gpl00 have been recently identified (16, 25- 
27). In this study, we demonstrated that the antigenic pep- 
tide recognized by TIL586 was derived from a second gene 
product of the gp75 gene.  To  our knowledge,  this  is  the 
first example that T  cells recognize an antigenic peptide re- 
sulting from the translation of an overlapping open reading 
frame of the same gene and the only example in eukaryotic 
cells that two completely different proteins and/or peptides 
can be translated from overlapping open reading frames of a 
single cellular gene. The ORF3 of the gp 75 gene encodes a 
short protein of 24 amino acids whose normal function,  if 
any,  is  unknown.  The  antigenic  peptide  recognized  by 
TIL586  is  encoded by the  sequence  located  immediately 
behind  the ATG  (294-296)  start  codon of the  alternative 
open reading frame. 
Although  gp75  shares  a  40-45%  amino  acid  sequence 
identity to tyrosinase, gpl00, and TRP-2, cotransfection of 
HLA-A31  and  tyrosinase, gplO0,  or  TRP-2  cDNAs,  re- 
spectively,  into  COS-7  cells  failed  to stimulate  GM-CSF 
release from T  cell clones derived from TIL586. A database 
search  did not reveal any proteins that had the HLA-A31 
peptide  binding motif and significant sequence  homology 
to  the  peptide  epitope  recognized by TIL586 and  its  de- 
rived  T  cell  clones.  In addition,  previous  studies  showed 
that  melanoma  transfectants  (gp75+/A31 +)  conferred  the 
ability  to  stimulate  GM-CSF  release  from  TIL586,  but 
gp75- melanoma transfectants  (gp75-/A31 +) did not (18). 
Similar  results  were  obtained  with  additional  melanoma 
cell lines (gp75-/A31+). These results suggested that it was 
unlikely  that  TIL586  recognized  the  epitope  peptide  de- 
rived from other known genes.  Since the ORF3P peptide 
was  the  only epitope  identified  from the  gp75  gene  and 
was recognized by six T  cell clones derived from TIL586, 
this peptide may be identical or similar to the naturally pro- 
cessed  peptide  on tumor  cells  and  melanocytes.  This  was 
further  supported  by  cold-target  inhibition  experiments, 
since this peptide was capable of competing for T  cell rec- 
1136  A Novel Human Cancer Antigen Table 2.  Identification of Antigenic Peptides with Reactivity to TIL586 
Target cells pulsed with peptide 
TIL586 
GM-CSF release  Percent specific lysis (E/T ratio 20:1) 
Experiment A 
Peptides  derived from ORF2 
586EBV +  peptide ISQDTTVGP-  <50  <10 
586EBV +  peptide AISQDTTVGR  <50  <10 
586EBV +  peptide AGEELPVTP.  <50  <10 
Peptides  derived from OP.F3 
586EBV +  peptide LWDVPSWLER  <50  < 10 
586EBV +  peptide MSLQRQFLR.  >8,000  60 
586EBV +  none  <50  <10 
586mel  +  none  >5,000  47 
Experiment B 
Modified peptides  of  MSLQP.QFLR 
586EBV +  peptide MSLQP.QFLR  >8,000  63 
586EBV +  pelxide MSLQRQFLIkT  <50  <10 
586EBV +  peptide SLQP.QFLRT  <50  <10 
586EBV +  peptide ~QR.QFLP.  >5,000  54 
586EBV +  peptide M/~LQP.QFLR  <50  <10 
586EBV +  peptide ~QRQFLR  <50  <10 
586EBV +  pepdde MSLQI~_FLR  <50  <10 
586EBV +  peptide MSLQRQFLE  <50  <10 
586EBV -F peptide MSLQRQFL  .K  <50  < 10 
586EBV +  none  <50  <10 
586mel  +  none  >5,000  48 
Conditions for peptide incubation with 586EBV B cells and GM-CSF release assay were the same as described in Table 1. GM-CSF secretion by 
TIL586 alone without stimulators was subtracted. Modified peptides were made by substitution of amino acid at positiom 2, 6, and 9 reladve to 
MSLQRQFLR. Cytotoxic lysis ofpeptide-pulsed  586EBV by TIL586 was done in a 4-b 5tCr release assay. 
ognition  with  a  natural  peptide  on tumor cells.  However, 
we could not exclude the possibility that these T  cells may 
cross-react  with  another  peptide  derived  from  a  distinct 
protein on tumor cells and melanocytes, since we have not 
directly isolated the ORF3P peptide from tumor cells. 
It was reported that T  cell-epitope peptides derived from 
the  frameshift  of the  mutated  adenomatosis  polyposis coli 
gene in colon cancer were recognized by CTLs generated 
from vaccinated BALB/c mice (28).  The results shown in 
Fig. 3  indicated  that the ATG at nucleotides 294-296 was 
required for translation of  the 24-amino acid product, which, 
in turn, was processed to the antigenic peptide recognized 
by TIL586. TIL586 still  recognized the mutated synthetic 
peptide pulsed on 586EBV B cells, but not the mutated gene 
when cotransfected into COS-7 cells with HLA-A31 cDNA, 
indicating that the loss of recognition of the mutated (ATG 
to ATC) gene by TIL586 resulted from elimination of trans- 
lation  of the  ORF3  product.  These  results  plus DNA  se- 
quence  analysis ruled out the possibility that the antigenic 
peptide recognized by TIL586 was derived from the frame- 
shift product ofgp75. It is possible, therefore, that multiple 
peptides  or proteins  are often translated  from overlapping 
open reading frames of a  single  eukaryotic gene,  but that 
means  to  detect  these  alternate  products  have  not  been 
available. The exquisite sensitivity of T  cells which can de- 
tect  naturally processed peptides  may allow  one to reveal 
many other examples of this phenomenon. 
The mechanism by which the overlapping ORF3 is trans- 
lated is currently unclear. Although examples have been re- 
ported  of cellular mRNAs that  initiate  at  more  than  one 
AUG codon (29, 30), and that,  in some rare cases,  initiate 
at both AUG and non-AUG codons such as CUG to gen- 
erate NH2-terminally extended identical sequences (21, 23), 
the use of overlapping open reading frames (i.e.,  translating 
two  completely dissimilar  peptides)  from a  single  eukary- 
otic cellular mRNA  has to our knowledge never been de- 
scribed. Several examples of translation of overlapping open 
reading frames from a single mRNA  have been described, 
but they are exclusively limited to viral genes (31-34). The 
detection  of the  products  of overlapping  open  reading 
frames in viral genes has been possible because of the exist- 
ence  of reactive  antibodies  in  the  sera  of virally  infected 
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Figure 5.  Inhibition oflysis of~tCr-labeled  target cells 
by nonlabeled 586EBV cells loaded with the O1KF3P 
peptide. (A) 586mel cells were labeled  with 51Cr for 90 
rnin  as  a  "hot"  target. 586EBV cells pulsed with 
O1KF3P (--4k--), with irrelevant peptide (-G--), and 
T2  cells loaded with  ORF3P  (-qZ]-) were used as 
"cold" target cells. After washing, hot and cold target 
cells were counted again and mixed at the cold/hot ra- 
tios of 1, 5, 10, and 20:1. TIL586 was added at an el- 
lector/hot target (E/T) ratio of 20:1. SICr release was 
measured after a 4-h  incubation. (B)  Lysis of SlCr- 
labeled 624mel (hot target) by T1L1200, which recog- 
nized gpl00, was not inhibited by 586EBV cells pulsed 
with  OIKF3P (~)  compared with  586EBV cells 
pulsed with an irrelevant  peptide (--&-). Cold and hot 
target cells were mixed at the indicated  ratios. TILl200 
was added at an effector/hot target (E/T) ratio of 30:1. 
Cytolytic activity of TILl200 was evaluated in a 4-h 
5, Cr release assay￿9 
hosts.  In our  case,  we  used  a  T  cell  assay  to  identify the 
epitope  peptide  recognized  by  T  cells.  This  approach  is 
very different from and more sensitive than conventional 
Western blots  or  immunoprecipitation analyses  (35).  Al- 
though there are five ATG codons between the authentic 
start codon of gp75 protein and the start codon of ORF3, 
the construct pPC1K110 covering the NH2-terminal part of 
O1KF1 (gp75) and the entire O1KF2 and ORF3 (nucleotides 
1-667) still retained the ability to stimulate cytokine release 
from TIL586. The level of stimulation by pPC1K110, how- 
ever, was severalfold lower than that stimulated by the 5' 
truncated (lacking the first 246  nucleotides) form of gp75 
(Fig.  1,  A  and  B),  suggesting  that  the  upstream  ATG 
codons  may  have  partially  inhibited  the  expression  of 
O1KF3. Several factors have made it possible to  detect the 
expression of the ORF3 product in this system. First, the 
upstream ATG codons preceding the ATG start codon of 
O1KF3 did not appear to be in the optimal context, which 
may allow use of the downstream ATG as start codons by 
the leaky scanning model. Second, the relatively high ex- 
pression of transfected genes in COS-7 cells and the avail- 
ability of the T  cell assay  as  an extremely sensitive means 
may  allow  us  to  detect  very low  levels  of the  translated 
products. 
Interestingly, the O1KF3 product was detected by T  cells 
in the  tumor cells as well as normal melanocytes (Fig. 6), 
strongly suggesting that the ORF3 protein was not a gene 
product resulting from genetic alterations in tumor cells. In 
previous studies, it was shown that TIL586 recognized mul- 
tiple tumor cell lines (gp75+/A31 +)  tested, suggesting that 
TIL586  recognizes  a  nonmutated,  shared  tumor  antigen 
(18). Since the gp75 gene is highly expressed in melanomas 
based  on  Northern  blot  and  PC1K  analyses  (18),  and  its 
gene product gp75 protein is the most abundant intracellu- 
lar glycoprotein expressed in melanoma cells and melano- 
cytes (36-38), it is not surprising that the T  cell clones rec- 
ognized the O1KF3P peptide when pulsed onto 586EBV B 
cells (A31+), and also recognized melanoma (gp75+/A31 +) 
as well as A31 + melanocytes, but not gp75-/A31 +  mela- 
noma cells or  O1KF3P pulsed on non-A31 T2  cells.  An- 
other possibility to explain the peptide expression in tumor 
cells and melanocytes is that O1LF3 may be translated from 
a  separate  mlLNA transcript(s) generated by an alternative 
splicing of gp75  mRNA  or a  different promoter.  To  our 
knowledge,  mRNA  transcripts  generated  by  alternative 
splicing are  translated into isoform proteins by use of the 
same open reading frames. In our case, however, a separate 
transcript may be generated and used as a template for trans- 
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Figure 6.  Recognition of the antigenic peptide by T cell clones from 
the T[L586 cell line. T cell clones were generated by limiting dilution 
(1 cell/well) from the TIL586 cell line. T  cell clones were further ex- 
panded in AIM-V medium containing 6,000 IU/ml 1L-2. 586EBV B 
cells were pulsed with the ORF3P peptide or irrelevant peptide for 90 
rain at 37~  After  washing  three times, T cell clone or TIL586 cells were 
added and coincubated  for an additional 18-24 h. For 586mel, 397mel/ 
A31 + tumors, and melanocyte  NHEM680 cells, t05 cells/well  were incu- 
bated with  10  s  cells of T  cell cones, TIL586-C1, TIL586-C4 and 
TIL586-C6, or TIL586 for 18-24 h. GM-CSF assay was performed as 
described in Fig. 1. 
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0  2000  4000  6000 8000 lation, but a completely different open reading frame rela- 
tive to gp75 was used to translate the ORF3 product.  The 
complete  structural  organization  of gp75  is  presently  un- 
known.  Further  experiments  are  needed  to  clarify  the 
mechanisms for the translation of the ORF3 protein. Nev- 
ertheless,  the possibilities  mentioned above are not mutu- 
ally exclusive. 
Several  years  ago,  the  pepton  hypothesis  was  proposed 
by Boon and Van Pel (39) to explain the observation that a 
short piece ofpromoterless subgenic DNA fragments trans- 
fected into P1 tumor cells directed the synthesis and surface 
expression  of P91A turn-  antigen.  This  hypothesis,  how- 
ever,  requires  an  unidentified  new RNA  polymerase  and 
other factors to direct transcription  and states that peptons 
are  expressed  in all  tissues  (39,  40).  Although  the  pepton 
hypothesis explains  a  surprising  observation,  it fails  to ex- 
plain how an alternative  open reading frame was translated 
from gp75 mRNA,  and  the  tissue  specificity of this  gene 
expression.  The  gp75  gene  expression  requires  a  classic 
RNA polymerase II promoter such as CMV promoter and 
the normal gp75 promoter. 
In summary, the gp75 gene encodes two gene products, 
the 24-amino acid peptide of ORF3, which was processed 
to an antigenic peptide recognized by T  cells,  and the gp75 
protein,  which was previously identified  as  an antigen  by 
IgG antibodies  in the  sera from a patient with melanoma. 
The infusion  of TIL586 plus  IL-2 into an autologous pa- 
tient  with  metastatic  melanoma  resulted  in  the  objective 
regression  of tumor  (17).  These  results  suggest  that  the 
MSLQRQFLR  peptide  derived  from  ORF3  and  recog- 
nized by TIL586 is  a tumor rejection  antigen.  The prod- 
ucts of this gene may be promising candidates for develop- 
ing  immunotherapeutic  strategies  for  the  treatment  of 
patients with melanoma. 
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Note added in proof." The use of alternative  open reading frames for translating two gene products,  p16  INK4~ 
and p 19  ARF, from the p 16 tumor suppressor gene has recently been reported (41). 
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